The following is a blog post by our contributor and story reviewer Alan Cassels. He’s an expert on the marketing tricks employed by some in the pharmaceutical industry to increase sales — and he knows how to fold laundry, too.
The company is up to bat, with a drug that has already had two strikes, and they’re ready for the next pitch. Everyone is holding their breath: will they knock it out of the park this time or head back to the bench, crushed?
We’re talking about the June 4th hearings around flibanserin, a drug that has been mired in controversy ever since it was first touted as necessary chemical assistance for HSDD (Hypoactive Sexual Desire Disorder) in women, formerly know as a drooping libido. While it is hard to characterize its real effectiveness (the drug was tested against placebo instead of a glass of red wine or a partner who knows how to fold laundry), flibanserin has failed the approval test twice because it was shown only to be modestly effective and caused sleepiness, dizziness and nausea. The drug was before the FDA in June 2010 and was struck down in a 10 to 1 vote saying that it didn’t work any better than placebo. Last time it was being reviewed, in 2013, the FDA sent it back to the drawing board wanting more safety data.
This week’s coverage from the New York Times and Bloomberg outlined some of the safety issues and politics of creating what has been called the world’s first Pink Viagra. The drug is being pitched as addressing a basic gender inequality, and advocates say that a woman’s need to have a pill to enhance her sexual interest is only fair since there are already many drugs to enhance male sexuality. The advocates have argued that the FDA needs to help Even the Score (the name of the pro-flibanserin campaign).
Australian journalist Ray Moynihan wrote about the drug industry’s involvement in female sexual dysfunction (FSD) in the BMJ in 2003, a piece which later became a chapter in our book — Selling Sickness — on the creation and marketing of diseases. Calling FSD the “freshest, clearest example we have,” we reported on the phenomenon that in order to sell any drug, you first have to sell the disease. Female Sexual Dysfunction seemed to be largely, but not completely, a creation of the pharmaceutical industry. That’s the position of Leonore Tiefer, a psychologist at the New York University School of Medicine who has been on this beat for sixteen years, maintaining that most problems related to sex are psychological and relational, not medical. She says that much damage can be wrought by medicalizing female sexual health.
I talked to her again this week in her office in New York City where she is rushing about getting ready for the upcoming flibanserin hearings on June 4th. “What to expect?” I wondered and she said: “The smart money seems to be on a heavy risk management strategy.” What she means is that all the controversy over the disease (do women really need an FDA-approved aphrodisiac?) or the drug’s minimal effectiveness (the latest data shows that it produces an average of 4.4 satisfying sexual experiences per month versus 3.7 on placebo) seems to have been pushed aside: now they’re only talking about the drug’s safety.
“They seem very thoughtful about it,” she said, adding that they have developed “literature for pharmacists and doctors, as well as patient information.” She asked me: “Do you say ‘intentional red herring’ or just ‘red herring,’” underlining the fact that if you’ve got a questionable drug for a questionable condition, the key is to focus peoples’ attention elsewhere. In this case, the drug’s safety is the diversion.
Tiefer, who heads up the NewView Campaign, also wrote to me in an email: “the Big issue of the day will be DDI (drug-drug interactions) and whether warnings will be sufficient.” A big concern centers around the uncertainty of mixing alcohol and flibanserin. One of the memorandums filed in advance of the FDA hearing said that “no known risk management strategy will eliminate the risks of hypotension/syncope associated with flibanserin use alone or the exacerbated risks of hypotension/syncope when combined with alcohol.”
Let’s see. I might be naïve to this, but trying to improve sexual desire and eliminating alcohol? Hmm. I guess it’s possible. But is it likely? Even though the manufacturer will trip over itself trying to produce written information packages and so on to try to demonstrate the drug can be taken safely, Leonore Tiefer wonders about the marketing strategy.
She riffs: “Would ‘Pink Viagra for teetotallers, only!’ work?”
We’ll find out on Thursday.
Addendum on Thursday June 4: The Food and Drug Administration (FDA) Advisory Committee voted 18-6 today to recommend approval of flibanserin. Many of the 18 said they voted “yes” with significant concerns. The Advisory Committee recommendation is not binding on the FDA, but such recommendations are usually not overturned.
Addendum on Friday June 5: See Alan Cassels’ followup post, “Astroturfers rule the day: FDA’s flibanserin reviewers were “emotionally blackmailed” by a slick lobbying campaign.”
Comments (3)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
felonious grammar
June 3, 2015 at 5:03 pmUp next, a drug to make you like your boss.
Carolyn Thomas
June 4, 2015 at 7:45 amFlibanserin, again? Alan, I first wrote about this drug six years ago when regulators were on the verge of denying early approval. Your alternative prescription for “a glass of red wine or a partner who knows how to fold laundry” is brilliant, effective, and with far fewer side effects than flibanserin (nausea, fatigue, dizziness, or the insomnia that forced up to 18% of women in trials to give up on the drug).
And it also reminds me of the sex ed lessons from the Cambridge Women’s Pornography Collective, who asked women the eternal question: “What really, really gets you hot?” – which resulted in a hilarious photo book called ‘Porn For Women’. Its cover illustrates a man doing the vacuuming (pictured here: http://ethicalnag.org/2009/11/15/boehringer-desire-drug/ ) The book’s answers describe a fantasy world where men give their partners exactly what they want: clothes get folded just so, delicious dinners await, and flatulence is just not that funny. Photos are entertainingly accompanied by steamy captions like: “As long as I have two legs to walk on, you’ll never take out the trash.”
Really funny – and no side effects!
regards,
C.
Flem
June 4, 2015 at 1:03 pmPlease stop associating the alleged unethical behavior of individual drug companies to the industry as a whole. It unfair and unproductive.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like